Cargando…

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography

Since emergence of the initial SARS-CoV-2 BA.1, BA.2 and BA.5 variants, Omicron has diversified substantially. Antigenic characterization of these new variants is important to analyze their potential immune escape from population immunity and implications for future vaccine composition. Here, we des...

Descripción completa

Detalles Bibliográficos
Autores principales: Rössler, Annika, Netzl, Antonia, Knabl, Ludwig, Bante, David, Wilks, Samuel H., Borena, Wegene, von Laer, Dorothee, Smith, Derek J., Kimpel, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460376/
https://www.ncbi.nlm.nih.gov/pubmed/37633965
http://dx.doi.org/10.1038/s41467-023-41049-4
_version_ 1785097630288707584
author Rössler, Annika
Netzl, Antonia
Knabl, Ludwig
Bante, David
Wilks, Samuel H.
Borena, Wegene
von Laer, Dorothee
Smith, Derek J.
Kimpel, Janine
author_facet Rössler, Annika
Netzl, Antonia
Knabl, Ludwig
Bante, David
Wilks, Samuel H.
Borena, Wegene
von Laer, Dorothee
Smith, Derek J.
Kimpel, Janine
author_sort Rössler, Annika
collection PubMed
description Since emergence of the initial SARS-CoV-2 BA.1, BA.2 and BA.5 variants, Omicron has diversified substantially. Antigenic characterization of these new variants is important to analyze their potential immune escape from population immunity and implications for future vaccine composition. Here, we describe an antigenic map based on human single-exposure sera and live-virus isolates that includes a broad selection of recently emerged Omicron variants such as BA.2.75, BF.7, BQ, XBB and XBF variants. Recent Omicron variants clustered around BA.1 and BA.5 with some variants further extending the antigenic space. Based on this antigenic map we constructed antibody landscapes to describe neutralization profiles after booster immunization with bivalent mRNA vaccines based on ancestral virus and either BA.1 or BA.4/5. Immune escape of BA.2.75, BQ, XBB and XBF variants was also evident in bivalently boosted individuals, however, cross-neutralization was improved for those with hybrid immunity. Our results indicate that future vaccine updates are needed to induce cross-neutralizing antibodies against currently circulating variants.
format Online
Article
Text
id pubmed-10460376
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-104603762023-08-28 Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography Rössler, Annika Netzl, Antonia Knabl, Ludwig Bante, David Wilks, Samuel H. Borena, Wegene von Laer, Dorothee Smith, Derek J. Kimpel, Janine Nat Commun Article Since emergence of the initial SARS-CoV-2 BA.1, BA.2 and BA.5 variants, Omicron has diversified substantially. Antigenic characterization of these new variants is important to analyze their potential immune escape from population immunity and implications for future vaccine composition. Here, we describe an antigenic map based on human single-exposure sera and live-virus isolates that includes a broad selection of recently emerged Omicron variants such as BA.2.75, BF.7, BQ, XBB and XBF variants. Recent Omicron variants clustered around BA.1 and BA.5 with some variants further extending the antigenic space. Based on this antigenic map we constructed antibody landscapes to describe neutralization profiles after booster immunization with bivalent mRNA vaccines based on ancestral virus and either BA.1 or BA.4/5. Immune escape of BA.2.75, BQ, XBB and XBF variants was also evident in bivalently boosted individuals, however, cross-neutralization was improved for those with hybrid immunity. Our results indicate that future vaccine updates are needed to induce cross-neutralizing antibodies against currently circulating variants. Nature Publishing Group UK 2023-08-26 /pmc/articles/PMC10460376/ /pubmed/37633965 http://dx.doi.org/10.1038/s41467-023-41049-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Rössler, Annika
Netzl, Antonia
Knabl, Ludwig
Bante, David
Wilks, Samuel H.
Borena, Wegene
von Laer, Dorothee
Smith, Derek J.
Kimpel, Janine
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
title Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
title_full Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
title_fullStr Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
title_full_unstemmed Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
title_short Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
title_sort characterizing sars-cov-2 neutralization profiles after bivalent boosting using antigenic cartography
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460376/
https://www.ncbi.nlm.nih.gov/pubmed/37633965
http://dx.doi.org/10.1038/s41467-023-41049-4
work_keys_str_mv AT rosslerannika characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT netzlantonia characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT knablludwig characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT bantedavid characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT wilkssamuelh characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT borenawegene characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT vonlaerdorothee characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT smithderekj characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography
AT kimpeljanine characterizingsarscov2neutralizationprofilesafterbivalentboostingusingantigeniccartography